Tracon Pharmaceuticals, Inc. (TCON)

Oncology Corporate Profile

Stock Performance

7.4400
-0.0300

HQ Location

8910 University Center Lane, Suite 700
San Diego, CA 92122

Company Description

TRACON develops targeted therapies for cancer, AMD and fibrotic diseases. TRACON's current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of renal cell carcinoma, soft tissue sarcoma, hepatocellular carcinoma, glioblastoma and choriocarcinoma, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates

Website: http://www.traconpharma.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
TRC105chimeric monoclonal antibody (inhibits CD105 - humanized)AngiosarcomaIII
TRC102alkylating agent potentiatorGlioblastoma Multiforme (GBM)II
TRC105chimeric monoclonal antibody (inhibits CD105 - humanized)Hepatocellular carcinoma (HCC)II
TRC102alkylating agent potentiatorMesotheliomaII
TRC105chimeric monoclonal antibody (inhibits CD105 - humanized)Renal cell carcinoma (RCC)II
TRC105chimeric monoclonal antibody (inhibits CD105 - humanized)Breast cancerI
TRC105chimeric monoclonal antibody (inhibits CD105 - humanized)Lung cancerI
TRC102alkylating agent potentiatorLung cancerI
TRC102alkylating agent potentiatorVarious cancer typesI

View additional information on product candidates here »

Pipeline image

Source


http://www.traconpharma.com

Recent News Headlines

TRACON Pharmaceuticals Announces TRC694 Data Presentation at Upcoming AACR Annual Meeting

3/27/2017 08:00 pm

[GlobeNewswire] - SAN DIEGO, March 27, 2017-- TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related ...

TRACON Pharmaceuticals Announces $21 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC

3/14/2017 08:00 pm

[GlobeNewswire] - SAN DIEGO, March 14, 2017-- TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age? related ...

TRACON Pharmaceuticals to Present at the 29th Annual Roth Conference

3/6/2017 09:00 pm

[GlobeNewswire] - SAN DIEGO, March 06, 2017-- TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related ...

Tracon reports 4Q loss

2/28/2017 10:01 pm

Tracon reports 4Q loss

2/28/2017 10:01 pm

TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update

2/28/2017 09:00 pm

[GlobeNewswire] - SAN DIEGO, Feb. 28, 2017-- TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age? related ...

TRACON to Report Fourth Quarter and Full Year 2016 Company Highlights and Financial Results on February 28, 2017

2/21/2017 09:00 pm

[GlobeNewswire] - SAN DIEGO, Feb. 21, 2017-- TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related ...

TRACON Pharmaceuticals Announces First Patient Dosed in Phase 3 TAPPAS Trial of TRC105 in Angiosarcoma

2/16/2017 01:00 pm

[GlobeNewswire] - SAN DIEGO, Feb. 16, 2017-- TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related ...

TRACON Pharmaceuticals Announces Top-line Results from NCI-Sponsored Phase 2 Trial of TRC105 in Recurrent Glioblastoma

2/9/2017 09:00 pm

[GlobeNewswire] - Combination of TRC105 and Avastin did not improve the median progression free survival versus single agent Avastin in recurrent glioblastoma patients. Combination was associated with a non-significant ...